Melanie C. Ruzek

AbbVie (United States) — United States

Immunology and Microbiology · Life Sciences

23h-index2.5kcitations64works11.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

T-cell and B-cell Immunology(19), Immune Cell Function and Interaction(19), Immunotherapy and Immune Responses(10), Hematopoietic Stem Cell Transplantation(6), Monoclonal and Polyclonal Antibodies Research(6)

Publications64 total

Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways
Nature Communications·2024Open Access
Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways
Nature Communications·2024· 21 citedOpen Access
An anti–TNF–glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases
Science Translational Medicine·2024· 23 cited
Understanding mechanisms of JAK1 inhibition on synovial fibroblasts using combinatorial approaches of bulk and single cell RNAseq analyses
Clinical and Experimental Rheumatology·2024Open Access
4-Octyl itaconate reduces influenza A replication by targeting the nuclear export protein CRM1
Journal of Virology·2023· 20 citedOpen Access
A first‐in‐human study of the novel immunology antibody–drug conjugate, ABBV‐3373, in healthy participants
British Journal of Clinical Pharmacology·2023· 13 citedOpen Access
Itaconate enhances oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways
Research Square (Research Square)·2023Open Access
POS1025 COMBINATION OF BULK AND SINGLE CELL RNASEQ ANALYSES TO REVEAL MECHANISMS OF ABT-317 (JAK INHIBITOR) ON SYNOVIAL FIBROBLASTS
Annals of the Rheumatic Diseases·2023· 3 citedOpen Access
Synovial Inflammatory Pathways Characterize <scp>Anti‐TNF</scp>–Responsive Rheumatoid Arthritis Patients
Arthritis & Rheumatology·2022· 26 cited
Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages
Cell Metabolism·2022· 295 cited
S808 Mechanisms of Non-Response to Adalimumab on Inflammatory Bowel Disease: Peripheral Proteomic and Transcriptomic Profiling from the SERENE-CD and SERENE-UC Studies
The American Journal of Gastroenterology·2021
S809 A Higher Induction Dosing Regimen of Adalimumab Does Not Enhance Modulation of Downstream Blood Molecular Markers in Patients With Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis
The American Journal of Gastroenterology·2021
Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression
Journal of Investigative Dermatology·2021· 13 cited
POS0365 ANTI-TNF GLUCOCORTICOID RECEPTOR MODULATOR ANTIBODY DRUG CONJUGATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
Annals of the Rheumatic Diseases·2021· 13 cited
Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa*
British Journal of Dermatology·2021· 21 cited
Biomarkers for the clinical development of antiviral therapies
Cytometry Part B Clinical Cytometry·2020· 5 citedOpen Access
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation
Cell Metabolism·2020· 543 citedOpen Access
Dual Blockade of Interleukin-1β and Interleukin-17A Reduces Murine Arthritis Pathogenesis but Also Leads to Spontaneous Skin Infections in Nonhuman Primates
Journal of Pharmacology and Experimental Therapeutics·2018· 9 citedOpen Access
Safety, Tolerability, and Pharmacodynamics of <scp>ABT</scp> ‐122, a Tumor Necrosis Factor– and Interleukin‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis
Arthritis & Rheumatology·2017· 30 citedOpen Access
FRI0034 Adalimumab reduces CXCR4 expression during inflammatory arthritis and in fibroblast-like synoviocytes and osteoclasts under chronic TNF exposure
Annals of the Rheumatic Diseases·2017· 1 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Susan Richards(10), Richard D. Garman(10), John M. Williams(8), Christine A. Biron(6), Ambika Mathur(5), Luke O'neill(4), Kathleen S. Neff(4), James Waire(4), Heikki Mansikka(4), Robert J. Padley(4), Yunan Zheng(3), Andrew H. Miller(3), Bradley D. Pearce(3), Steve Ledbetter(3), Sharon Nahill(3), Abraham Scaria(3), John L. Dzuris(3), Donna Conlon(3), Carolyn A. Cuff(3), Shaughn H. Bryant(3)